Burosumab, a humanized monoclonal antibody for FGF23 which will increase renal tubular reabsorption of phosphate represents a promising treatment option for hypophosphatemic osteomalacia in McCune-Albright syndrome, however further clinical trials are needed to establish standardized protocols. The gene discussed is FGF23; the disease is McCune-Albright syndrome.